RE: 73712 Jan 2023 20:44
I
LONDON, Jan. 09, 2023 (GLOBE NEWSWIRE) -- NovalGen Ltd (“NovalGen”), a biopharmaceutical company developing breakthrough cancer therapies, alongside a disruptive auto-regulation platform, today announces the appointment of Dr Michael Owen and Mr Scott Clark as Non-Executive Directors to its Board, effective January 2023.
“Both Mike and Scott are highly experienced industry executives who bring a wealth of leadership and drug development experience, and they will be an asset to our Board of Directors,” said Professor Amit Nathwani, Founder and CEO of NovalGen. “NovalGen is at a transformational stage in its development as we progress our lead product through the clinic as well as drive our pre-clinical programmes, including our first-in-class half-life extended T cell engager targeting ROR-1 with autoregulation capability, which demonstrates the inherent value in both our pipeline and our technology base.”
Dr Michael Owen has worked in biomedical research, and in the pharmaceutical and biotechnology industries for over 40 years. He currently serves as a director on four boards. He is the Chairman of Ossianix Inc, a privately held biotechnology company, and is also on the boards of Zealand Pharma A/S, ReNeuron plc and Sareum Holdings plc. Dr Owen is also an advisor to several Venture Capital LPs and is Chairman of Avacta plc’s SABs. Prior to board services, Dr Owen co-founded and served as the first CSO of Kymab Ltd, a biopharmaceutical company recently acquired by Sanofi. Prior to co-founding Kymab, he worked for GSK where he was SVP and Head of Research for Biopharmaceuticals R&D. Prior to joining the Pharma industry, Dr Owen was a Principal Scientist at the ICRF London laboratories (now CRUK) where he was noted for his work on lymphocyte development and on the molecular basis of diversity in the adaptive immune system. He received a BA degree from Oxford University and a PhD from Cambridge University. He was elected a member of the European Molecular Biology Organisation and a Fellow of the Academy of Medical Sciences.
Sign In
Follow the stocks
